Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Cummings, Steven R., Martin, Javier San, McClung, Michael R., Siris, Ethel S., Eastell, Richard, Reid, Ian R., Delmas, Pierre, Zoog, Holly B. +8 more·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0809493

Cited by (1,006)

Items 401–500 of 1,006

  1. Glucocorticoids, Inflammation and Bone
    Melek Güler-Yüksel, Jos N. Hoes, Irene E. M. Bultink, Willem Frederik Lems · 2018 · Calcified Tissue International
  2. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial
    Chi Chiu Mok, Ling Yin Ho, Kwok Man Ma · 2015 · Bone
  3. Effects of RANKL-Targeted Therapy in Immunity and Cancer
    Michael L. Cheng, Lawrence H. Fong · 2014 · Frontiers in Oncology
  4. Tracking progesterone receptor-mediated actions in breast cancer
    Todd Philip Knutson, Carol Ann Lange · 2013 · Pharmacology & Therapeutics
  5. Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis
    Ramchand, Sabashini K, Leder, Benjamin Z · 2024 · The Journal of Clinical Endocrinology & Metabolism
  6. A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction
    Sato, Tadatoshi, Verma, Shiv, Andrade, Christian D. Castro, Omeara, Maureen, Campbell, Nia, Wang, Jialiang S., Cetinbas, Murat, Lang, Audrey, Ausk, Brandon J., Brooks, Daniel J. et al. · 2020 · Nature Communications
  7. Management of Glucocorticoid-Induced Osteoporosis
    René Rizzoli, Jonathan Derrick Adachi, Cyrus C. Cooper, Willard H. Dere, J. P. Devogelaer, Adolfo Díez‐Pérez, John А. Kanis, Andrea Laslop, Bruce Mitlak, Socrates E. Papapoulos et al. · 2012 · Calcified Tissue International
  8. Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study
    Jacques P. Brown, David W. Dempster, Beiying Ding, Ricardo E. Dent-Acosta, Javier San Martín, Andreas Grauer, Rachel B. Wagman, José Zanchetta · 2011 · Journal of Bone and Mineral Research
  9. The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future
    Samantha Pozzi, Noopur S Raje · 2011 · The Oncologist
  10. Increasing Options for the Treatment of Osteoporosis
    Sundeep Khosla · 2009 · New England Journal of Medicine
  11. Molecular biology of bone remodeling: Implications for new therapeutic targets for osteoporosis
    John Christopher Gallagher, Adarsh J. Sai · 2010 · Maturitas
  12. Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
    Albrecht Werner Popp, Nadshathra Varathan, Helene Buffat, Christoph Senn, Romain Perrelet, Kurt Lippuner · 2018 · Calcified Tissue International
  13. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis
    C. Edwards, E. Williams · 2010 · Osteoporosis International
  14. Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature
    Chang Hyun Byon, Yabing Chen · 2015 · Current Osteoporosis Reports
  15. Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis
    Talia Diker‐Cohen, Dana Rosenberg, Tomer Avni, Daniel Shepshelovich, Gloria Tsvetov, Anat Gafter‐Gvili · 2020 · The Journal of Clinical Endocrinology & Metabolism
  16. Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
    J.J. Body, Pierre Bergmann, Steven Boonen, J.-P. Devogelaer, Evelien Gielen, Stefan Goemaere, Jean‐Marc Kaufman, Serge Rozenberg, J.-Y. Reginster · 2012 · Osteoporosis International
  17. Management of osteoporosis in rheumatoid arthritis patients
    Jos N. Hoes, Irene E. M. Bultink, Willem Frederik Lems · 2015 · Expert Opinion on Pharmacotherapy
  18. Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis
    Kenneth E. S. Poole, Graham M. Treece, Andrew H. Gee, Jacques P. Brown, Michael R. McClung, Andrea Wang, Cesar R. Libanati · 2014 · Journal of Bone and Mineral Research
  19. Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
    Constantine S. Mitsiades, Faith E. Davies, Jacob P. Laubach, Douglas Joshua, Jesús F. San Miguel, Kenneth Carl Anderson, Paul Gerard Guy Richardson · 2011 · Journal of Clinical Oncology
  20. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group
    Mickaël Hiligsmann, Maribel Salas, Dyfrig Arwyn Hughes, Elizabeth Manias, Femida hussein Gwadry-Sridhar, Pat Linck, Warren Cowell · 2013 · Osteoporosis International
  21. The future of osteoporosis treatment – a research update
    Kurt Lippuner · 2012 · Swiss Medical Weekly
  22. Denosumab: A comprehensive review
    Prasad Narayanan · 2013 · South Asian Journal of Cancer
  23. RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia
    Benjamin Joachim Schmiedel, Carolin Andrea Scheible, Tina Nuebling, Hans‐Georg Kopp, Stefan Wirths, Miyuki Azuma, Pascal Schneider, Gundram Jung, Ludger Große‐Hovest, Helmut Rainer Salih · 2012 · Cancer Research
  24. RANKL: A therapeutic target for bone destruction in rheumatoid arthritis
    Sakae Tanaka, Yoshiya Tanaka, Naoki Ishiguro, Hisashi Yamanaka, Tsutomu Takeuchi · 2017 · Modern Rheumatology
  25. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome
    Felicia Cosman, Daria B. Crittenden, Serge Ferrari, Edward Michael Lewiecki, Juan José Jaller-Raad, Cristiano A. F. Zerbini, Cassandra E. Milmont, Paul D Meisner, Cesar R. Libanati, Andreas Grauer · 2018 · Journal of Bone and Mineral Research
  26. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone
    Takahiko Shibahara · 2019 · The Tohoku Journal of Experimental Medicine
  27. Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention
    Hennie G. Raterman, Irene E. M. Bultink, Willem Frederik Lems · 2020 · Expert Opinion on Pharmacotherapy
  28. Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK
    Ellen Schmuhl, Robert Ramer, Achim Salamon, Kirsten Peters, Burkhard Hinz · 2013 · Biochemical Pharmacology
  29. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis: Executive Summary of Recommendations
    Nelson B. Watts, John Paul Bilezikian, Pauline M. Camacho, Susan L. Greenspan, Steven T. Harris, Stephen F. Hodgson, Michael Kleerekoper, Marjorie M. Luckey, Michael R. McClung, Rachel Pessah‐Pollack et al. · 2010 · Endocrine Practice
  30. Denosumab‐associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting
    Andrew L. H. Huynh, Scott T. Baker, Andrew James Stewardson, Douglas Forsyth Johnson · 2016 · Pharmacoepidemiology and Drug Safety
  31. Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS)
    Silvana Di Gregorio, Luis del Río, Josep Rodríguez Tolrà, E. Bonel, M. García, Renaud Winzenrieth · 2015 · Bone
  32. Bilateral atypical femoral fractures in a patient prescribed denosumab — A case report
    Robin N. Thompson, Ciara L. Armstrong, Gary Heyburn · 2014 · Bone
  33. Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
    Ning Zhang, Zongkang Zhang, Yuanyuan Yu, Zhenjian Zhuo, Ge Zhang, Bao‐Ting Zhang · 2020 · Frontiers in Cell and Developmental Biology
  34. Osteoporosis: An Update on Screening, Diagnosis, Evaluation, and Treatment
    Shahbaaz A. Sabri, Joseph C. Chavarria, Cheryl L. Ackert‐Bicknell, Christine M. Swanson, Evalina L. Burger · 2022 · Orthopedics
  35. Effect of Bifidobacterium on osteoclasts: TNF-α/NF-κB inflammatory signal pathway-mediated mechanism
    Yue Wu, Yunjiao Yang, Lan Wang, Yiding Chen, Xuke Han, Lisha Sun, Huizhen Chen, Qiu Chen · 2023 · Frontiers in Endocrinology
  36. Current perspectives on the multiple roles of osteoclasts: Mechanisms of osteoclast–osteoblast communication and potential clinical implications
    Valentina Daponte, Katrin Henke, Hicham Drissi · 2024 · eLife
  37. Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
    Anju Parthan, Morgan Kruse, Nicole Yurgin, Joice Huang, Hema N. Viswanathan, Douglas C.A. Taylor · 2013 · Applied Health Economics and Health Policy
  38. An Open-Label, Prospective Pilot Clinical Study of Denosumab for Severe Hyperparathyroidism in Patients With Low Bone Mass Undergoing Dialysis
    Chien‐Liang Chen, Nai-Ching Chen, Chih‐Yang Hsu, Kang-Ju Chou, Po‐Tsang Lee, Hua-Chang Fang, Jenn-Huei Renn · 2014 · The Journal of Clinical Endocrinology & Metabolism
  39. Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis
    Roger Zebaze, Cesar R. Libanati, Michael R. McClung, José Zanchetta, David L. Kendler, Arne Didrik Høiseth, Andrea Wang, Ali Ghasemzadeh, Ego Seeman · 2016 · Journal of Bone and Mineral Research
  40. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system
    Yoshiya Tanaka, Takeshi Ohira · 2018 · Current Opinion in Pharmacology
  41. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study
    Charlotte L M Krieckaert, Michael Twahier Nurmohamed, Gertjan Wolbink, Willem Frederik Lems · 2012 · Lara D. Veeken
  42. Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High‐Resolution Peripheral Quantitative Computed Tomography Study
    Jiang Yue, James Francis Griffith, Fan Xiao, Lin Shi, Defeng Wang, Jiayun Shen, Priscilla C. H. Wong, Edmund K. Li, Martin Li, Tena K. Li et al. · 2016 · Arthritis Care & Research
  43. A comprehensive review of denosumab for bone metastasis in patients with solid tumors
    Gözde Gül, Mehmet Alı Nahıt Şendur, Sercan Aksoy, Ali Riza Sever, Kadri Altundağ · 2015 · Current Medical Research and Opinion
  44. Best Practice Guidelines for Assessment and Management of Osteoporosis in Adult Patients Undergoing Elective Spinal Reconstruction
    Zeeshan Mohammad Sardar, Josephine Rose Coury, Meghan K. Cerpa, Christopher J. DeWald, Christopher Pearson Ames, Christopher Shuhart, Colleen M. Watkins, David W. Polly, Douglas R. Dirschl, Eric O. Klineberg et al. · 2022 · eScholarship (California Digital Library)
  45. Managements of osteoporotic vertebral compression fractures: A narrative review
    Devon Patel, Jiayong Liu, Nabil A. Ebraheim · 2022 · World Journal of Orthopedics
  46. Bone Mineral Density Changes Among Women Initiating Proton Pump Inhibitors or H2 Receptor Antagonists: A SWAN Cohort Study
    Daniel H. Solomon, Susan J. Diem, Kristine M. Ruppert, Yin Lian, Chih-Chin Liu, Alyssa Wohlfart, Gail A. Greendale, Joel S. Finkelstein · 2014 · Journal of Bone and Mineral Research
  47. New roles of osteoblasts involved in osteoclast differentiation
    Teruhito Yamashita · 2012 · World Journal of Orthopedics
  48. Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography
    Michelle L. Frost, Musib M. Siddique, Glen Mervyn Blake, Amelia E.B. Moore, P.J. Schleyer, Joel Dunn, Edward J. Somer, Paul K. Marsden, Richard Eastell, Ignac Fogelman · 2010 · Journal of Bone and Mineral Research
  49. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response
    Dominic W. Pelle, Jonathan W. Ringler, Jacqueline D. Peacock, Kevin Kampfschulte, Donald J. Scholten, Mary Margaret Davis, Deanna S. Mitchell, Matthew R. Steensma · 2014 · Translational research
  50. Treatment needs and current options for postmenopausal osteoporosis
    Luigi Gennari, Stefano Rotatori, Simone Bianciardi, Ranuccio Nuti, Daniela Merlotti · 2016 · Expert Opinion on Pharmacotherapy
  51. Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis
    Yahui Grace Chiu, Christopher T. Ritchlin · 2016 · Expert Opinion on Biological Therapy
  52. Bone-Vascular Axis in Chronic Kidney Disease
    Pieter Evenepoel, Britt Opdebeeck, Karel David, Patrick C. D’Haese · 2019 · Advances in Chronic Kidney Disease
  53. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D
    Henriksen, Kim, Byrjalsen, Inger, Andersen, Jeppe R., Bihlet, Asger R., Russo, Luis A., Alexandersen, Peter, Valter, Ivo, Qvist, Per, Lau, Edith, Riis, Bente J. et al. · 2016 · Bone
  54. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
    Serge Ferrari, Jonathan Derrick Adachi, Kurt Lippuner, Carol Zapalowski, Paul D. Miller, Jean‐Yves Reginster, Ove Törring, David L. Kendler, Nadia S Daizadeh, A. Wang et al. · 2015 · Osteoporosis International
  55. Biologic therapies and systemic bone loss in rheumatoid arthritis
    Theodoros Dimitroulas, Spyros N. Nikas, Panagiotis Trontzas, George D. Kitas · 2013 · Autoimmunity Reviews
  56. Denosumab for Management of Parathyroid Carcinoma-Mediated Hypercalcemia
    Priyathama Vellanki, Karoline Lange, Dina M. Elaraj, Peter Andreas Kopp, Malek El Muayed · 2013 · The Journal of Clinical Endocrinology & Metabolism
  57. Effects of Denosumab Treatment and Discontinuation on Human Growth Plates
    Howard D. Wang, Alison M Boyce, Jeffrey Y. Tsai, Rachel Ilana Gafni, Frances A. Farley, Joséphine Z. Kasa-Vubu, Alfredo Molinolo, Michael Terrence Collins · 2014 · The Journal of Clinical Endocrinology & Metabolism
  58. Structure-based development of a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis
    Hai Minh Ta, Giang Thi Tuyet Nguyen, Hye Mi Jin, Jongkeun Choi, Hyejin Park, Nacksung Kim, Hye‐Yeon Hwang, Kyeong Kyu Kim · 2010 · Proceedings of the National Academy of Sciences
  59. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study
    Makoto Kajizono, Hikaru Sada, Yuhko Sugiura, Yoshihiko Soga, Yoshihisa Kitamura, Junji Matsuoka, Toshiaki Sendo · 2015 · Biological and Pharmaceutical Bulletin
  60. Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity
    Furuya, Yuriko, Inagaki, Atsushi, Khan, Masud, Mori, Kaoru, Penninger, Josef M., Nakamura, Midori, Udagawa, Nobuyuki, Aoki, Kazuhiro, Ohya, Keiichi, Uchida, Kohji et al. · 2013 · Journal of Biological Chemistry
  61. Drug-Related Adverse Events of Osteoporosis Therapy
    Moin Khan, Angela M. Cheung, Aliya Aziz Khan · 2016 · Endocrinology and Metabolism Clinics of North America
  62. Osteoporosis: Current and Emerging Therapies Targeted to Immunological Checkpoints
    Massimo De Martinis, Maria Maddalena Sirufo, Lia Ginaldi · 2019 · Current Medicinal Chemistry
  63. Osteoimmunology: The Crosstalk between T Cells, B Cells, and Osteoclasts in Rheumatoid Arthritis
    Mei Yang, Lei Zhu · 2024 · International Journal of Molecular Sciences
  64. Osteoporosis and osteopenia: implications for periodontal and implant therapy
    Joan Otomo‐Corgel · 2012 · Periodontology 2000
  65. A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures
    Francesca Gori, Ulf H. Lerner, Claes Ohlsson, Roland Baron · 2015 · BoneKEy Reports
  66. Treatment of post-menopausal osteoporosis: beyond bisphosphonates
    S. Ishtiaq, Ilana Fogelman, Geeta Hampson · 2014 · Journal of Endocrinological Investigation
  67. Genome-Wide Association Meta-Analysis of Cortical Bone Mineral Density Unravels Allelic Heterogeneity at the RANKL Locus and Potential Pleiotropic Effects on Bone
    Lavinia Paternoster, Mattias Lorentzon, Liesbeth Vandenput, Magnus K. Karlsson, Östen Ljunggren, Andreas Kindmark, Dan Mellström, John P. Kemp, Caroline Jarrett, Jeff M.P. Holly et al. · 2010 · PLoS Genetics
  68. New and emerging concepts in the use of denosumab for the treatment of osteoporosis
    Edward Michael Lewiecki · 2018 · Therapeutic Advances in Musculoskeletal Disease
  69. Osteoporosis and cardiovascular disease: a review
    Taoreed Adegoke Azeez · 2022 · Molecular Biology Reports
  70. Role of Hormone Therapy in the Management of Menopause
    Jan Leslie Shifren, Isaac Schiff · 2010 · Obstetrics and Gynecology
  71. Effect of ONO-5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2-Year Results From the OCEAN Study
    Richard Eastell, Shinichi Nagase, Maria Small, Steven Boonen, Tim D. Spector, Michiyo Ohyama, Tomohiro Kuwayama, Steve Deacon · 2013 · Journal of Bone and Mineral Research
  72. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy
    Kakoli Mukherjee, Naibedya Chattopadhyay · 2016 · Biochemical Pharmacology
  73. Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma
    Piers A. Blombery, Ella R. Thompson, Georgina L. Ryland, Rachel Joyce, David J. Byrne, Christine Khoo, Stephen Lade, Mark Hertzberg, Greg Hapgood, Paula V. Marlton et al. · 2018 · Oncotarget
  74. Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider
    Liana Tripto‐Shkolnik, Naama Fund, Vanessa Rouach, Gabriel Chodick, Varda Shalev, Inbal Goldshtein · 2019 · Bone
  75. Low-energy distal radius fractures in middle-aged and elderly men and women—the burden of osteoporosis and fracture risk
    Jannike Øyen, Clara Gram Gjesdal, Christina Elisabeth Brudvik, L. M. HOVE, Ellen Margrete Apalset, Hans Christian Gulseth, Glenn Haugeberg · 2009 · Osteoporosis International
  76. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection
    Sven Otto, Sebastian Baumann, Michael Ehrenfeld, Christoph Pautke · 2013 · Journal of Cranio-Maxillofacial Surgery
  77. An overview on the treatment of postmenopausal osteoporosis
    Sérgio Setsuo Maeda, Marise Lazaretti‐Castro · 2014 · Arquivos Brasileiros de Endocrinologia & Metabologia
  78. Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture
    Serge Ferrari, Jean‐Yves Reginster, Maria Luisa Brandi, John А. Kanis, Jean‐Pierre Devogelaer, Jean‐Marc Kaufman, Jean-Marc Féron, Andreas Kurth, René Rizzoli · 2016 · Archives of Osteoporosis
  79. Bacterial diversity in medication-related osteonecrosis of the jaw
    Fredrik Hallmer, Tore Bjørnland, Gunilla Andersson, Jonas P. Becktor, Anne Karin Kristoffersen, Morten Enersen · 2016 · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology
  80. Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
    Zachary S. Bernstein, E. Bridget Kim, Noopur S Raje · 2022 · Cells
  81. Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice
    Vagelis E. Rinotas, Alexandra Niti, Romain Dacquin, Nicolas Bonnet, Marina Stolina, Chun-Ya E. Han, Paul J. Kostenuik, Pierre Jurdic, Serge Ferrari, Eleni K. Douni · 2013 · Journal of Bone and Mineral Research
  82. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis
    Paul D. Miller · 2011 · Therapeutic Advances in Musculoskeletal Disease
  83. The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation
    Luisella Cianferotti, Francesco Bertoldo, Marco Carini, John А. Kanis, Alberto Lapini, Nicola Longo, Giuseppe Ettore Martorana, Vincenzo G. Mirone, Jean‐Yves Reginster, René Rizzoli et al. · 2017 · Oncotarget
  84. Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis
    Antonio Naranjo, Petra Díaz del Campo Fontecha, María Pilar Aguado Acín, Luis Marcelino Arboleya Rodríguez, E. Casado, Santos Castañeda, Jordi Fiter Aresté, Laia Gifre, Carmen Gómez Vaquero, Gloria Candelas et al. · 2018 · Reumatología Clínica
  85. The effect of exercise intensity on bone in postmenopausal women (part 1): A systematic review
    Melanie Kistler-Fischbacher, Benjamin K. Weeks, Belinda R. Beck · 2020 · Bone
  86. Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions
    Jeffrey R. Curtis, Monika M. Safford · 2012 · Drugs & Aging
  87. Bone Biology and Anabolic Therapies for Bone: Current Status and Future Prospects
    Thomas John Martin · 2014 · Journal of Bone Metabolism
  88. Denosumab
    Marit D Moen, Susan J. Keam · 2010 · Drugs & Aging
  89. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
    Natasha M. Appelman‐Dijkstra, Socrates E. Papapoulos · 2018 · Nature Reviews Endocrinology
  90. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates
    Paul D. Miller, Nicola Pannacciulli, Jorge Malouf, Andrea J. Singer, Edward J. Czerwinski, Henry G. Bone, C. Wang, S. Huang, Arkadi A. Chines, Willem Frederik Lems et al. · 2019 · Osteoporosis International
  91. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study
    Wolfgang Brozek, Berthold Reichardt, Jochen Zwerina, Hans Peter Dimai, Katharina Klaushofer, Elisabeth Zwettler · 2015 · Osteoporosis International
  92. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression
    Douglas C. Bauer, Dennis M. Black, Mary Bouxsein, Li‐Yung Lui, Jane A. Cauley, Anne E. de Papp, Andreas Grauer, Sundeep Khosla, Charles E. McCulloch, Richard Eastell · 2018 · Journal of Bone and Mineral Research
  93. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates
    Brigitte Uebelhart, René Rizzoli, Serge Ferrari · 2017 · Osteoporosis International
  94. Neuromuscular Diseases and Bone
    Giovanni Iolascon, Marco Paoletta, Sara Liguori, Claudio Curci, Antimo Moretti · 2019 · Frontiers in Endocrinology
  95. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project
    Richard Eastell, Eric Vittinghoff, Li‐Yung Lui, Charles E. McCulloch, Imre J. Pavo, Arkadi A. Chines, Sundeep Khosla, Jane A. Cauley, Bruce Mitlak, Douglas C. Bauer et al. · 2020 · Journal of Bone and Mineral Research
  96. Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases
    Frank Buttgereit, Andriko Palmowski, Milena Bond, Giovanni Adami, Christian Dejaco · 2024 · Nature Reviews Rheumatology
  97. Circular RNAs in the management of human osteoporosis
    Giuseppe Gargano, Simona M Pagano, Nicola Maffulli · 2024 · British Medical Bulletin
  98. Skeletal Diseases in Cushing’s Syndrome: Osteoporosis versus Arthropathy
    Kaltsas, Gregory, Makras, Polyzois · 2010 · Neuroendocrinology
  99. Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder
    Bashkim Kadriu, Philip W. Gold, David A. Luckenbaugh, Marc S. Lener, Elizabeth D. Ballard, Mark J. Niciu, Ioline D. Henter, Lawrence T. Park, R T De Sousa, P Yuan et al. · 2017 · Molecular Psychiatry
  100. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial
    Joy N. Tsai, Hang Lee, Natalie L. David, Richard Eastell, Benjamin Z. Leder · 2019 · The Lancet Diabetes & Endocrinology